GlassScriptPhysician profile
Kenneth Soonil Bark
NPI 1932303484
$49,683.22
in general payments reported to CMS, 2019-2025
23 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,203 · 2021: $21K · 2022: $5,322 · 2023: $4,720 · 2024: $1,436 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $2,313 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $2,312.53 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $46,319.13 | 2019-2024 | Da Vinci Surgical System |
| Abbvie INC. | $705.91 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $605.02 | 2021-2025 | Stelara, Tremfya, Simponi |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $500.00 | 2024 | |
| Medtronic, INC. | $323.74 | 2021-2024 | Interstim, Eea |
| Takeda Pharmaceuticals U.S.A., INC. | $307.89 | 2020-2025 | Entyvio |
| Aroa Biosurgery Incorporated | $218.00 | 2025 | |
| Vioptix INC | $136.45 | 2022 | |
| Amgen INC. | $98.33 | 2022-2023 | Amjevita, Avsola |
| Celgene Corporation | $64.79 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $55.99 | 2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.21 | 2023-2024 | Xifaxan, Plenvu |
| Axonics, INC. | $42.06 | 2023-2024 | Axonics |
| Ferring Pharmaceuticals INC. | $36.13 | 2021-2022 | |
| Hologic Sales and Service, LLC | $35.08 | 2025 | Coolseal Generator |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.94 | 2019-2022 | |
| Sandoz INC. | $26.32 | 2024 | Hyrimoz |
| Smith+Nephew, INC. | $26.20 | 2024 | Pico 7 |
| Medtronic USA, INC. | $23.64 | 2020 | |
| Alfasigma USA, INC. | $21.82 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.86 | 2022 | |
| Daiichi Sankyo INC. | $16.03 | 2020 | |
| Lsi Solutions INC | $14.68 | 2023 | Running Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Bark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.